Clinical data
Trade names former Mandol
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a601206
    Routes of
    Intramuscular, intravenous
    ATC code
    Legal status
    Legal status
    • UK: POM (Prescription only)
    • US: Discontinued
    Pharmacokinetic data
    Protein binding 75%
    Elimination half-life 48 minutes
    Excretion Mostly renal, as unchanged drug
    CAS Number
    PubChem CID
    ECHA InfoCard 100.047.285
    Chemical and physical data
    Formula C18H18N6O5S2
    Molar mass 462.505 g/mol
    3D model (JSmol)

    Cefamandole (INN, also known as cephamandole) is a second-generation broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally. Cefamandole is no longer available in the United States.

    The chemical structure of cefamandole, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase)(vitamin K supplement is recommended during therapy) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.

    Cefamandole has a broad spectrum of activity and can be used to treat bacterial infections of the skin, bones and joints, urinary tract, and lower respiratory tract. The following represents cefamandole MIC susceptibility data for a few medically significant microorganisms.

    • Escherichia coli: 0.12 - 400 μg/ml
    • Haemophilus influenzae: 0.06 - >16 μg/ml
    • Staphylococcus aureus: 0.1 - 12.5 μg/ml


    CO2 is generated during the normal constitution of cefamandole and ceftazidime, potentially resulting in an explosive-like reaction in syringes.[2]

    See also


    1. http://www.toku-e.com/Assets/MIC/Cefamandole%20sodium%20salt.pdf
    2. Stork CM (2006). "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA. Goldfrank's toxicologic emergencies. New York: McGraw-Hill. p. 847. ISBN 0-07-143763-0. Retrieved 2009-07-03.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.